Safety and efficacy of golimumab in Chinese patients with active ankylosing
spondylitis: 1-year results of a multicentre, randomized, double-blind,
placebo-controlled phase III trial.
Author(s): Bao C(1), Huang F(2), Khan MA(2), Fei K(2), Wu Z(2), Han C(2), Hsia EC(3).
Affiliation(s): Author information:
(1)Shanghai Renji Hospital, Shanghai, Chinese PLA General Hospital, Beijing,
China, Case Western Reserve University, Cleveland, OH, Janssen Research &
Development, LLC, Spring House, PA and University of Pennsylvania School of
Medicine, Philadelphia, PA, USA. hap//contradistinctionst2/show/NCT01248793
baochunde_1678@126.com. (2)Shanghai Renji Hospital, Shanghai, Chinese PLA General
Hospital, Beijing, China, Case Western Reserve University, Cleveland, OH, Janssen
Research & Development, LLC, Spring House, PA and University of Pennsylvania
School of Medicine, Philadelphia, PA, USA.
hap//contradistinctionst2/show/NCT01248793. (3)Shanghai Renji Hospital, Shanghai,
Chinese PLA General Hospital, Beijing, China, Case Western Reserve University,
Cleveland, OH, Janssen Research & Development, LLC, Spring House, PA and
University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
hap//contradistinctionst2/show/NCT01248793Shanghai Renji Hospital, Shanghai,
Chinese PLA General Hospital, Beijing, China, Case Western Reserve University,
Cleveland, OH, Janssen Research & Development, LLC, Spring House, PA and
University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
hap//contradistinctionst2/show/NCT01248793.
Publication date & source: 2014, Rheumatology (Oxford). , 53(9):1654-63
OBJECTIVE: The aim of this study was to assess the efficacy and safety of
golimumab in Chinese patients with active AS.
METHODS: Two hundred and thirteen patients were randomized in a 1:1 ratio to
receive either s.c. injections of placebo from weeks 0 to 20 followed by
golimumab 50 mg from weeks 24 to 48 (group 1, n = 105) or golimumab 50 mg from
weeks 0 to 48 (group 2, n = 108), both every 4 weeks. Placebo crossover occurred
at week 24, while early escape was at week 16. The primary endpoint was an
improvement of at least 20% in the Assessment of SpondyloArthritis international
Society (ASAS20) criteria at week 14. Major secondary endpoints included week 24
ASAS20 response and week 14 change scores for BASFI and BASMI.
RESULTS: Golimumab treatment elicited significantly better responses than placebo
in week 14 ASAS20 response [49.1% (53/108) vs 24.8% (26/105), respectively, P <
0.001], week 24 ASAS20 response (50.0% vs 22.9%, P < 0.001) and mean improvements
in BASFI (-1.26 vs 0.11, P < 0.001) and BASMI (-0.42 vs -0.19, P = 0.021) scores
at week 14. Additionally, golimumab treatment led to significant improvements in
the mental and physical components of health-related quality of life (HRQoL) and
sleep problems at week 24, all of which were further improved through week 52.
During the 16-week placebo-controlled study period, 31.4% and 30.6% of patients
had adverse events (AEs) in groups 1 and 2, respectively; similar AE reporting
rates were observed through week 24 (34.3% and 32.0%) and among the
golimumab-treated patients through week 56 (41.2%).
CONCLUSION: Golimumab significantly reduced clinical symptoms/signs and improved
physical function, range of motion and HRQoL in Chinese patients with active AS
without unexpected safety concerns.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT01248793.
|
